Our Goal
Osivax is leveraging its oligoDOMTM self-assembling nanoparticles platform technology to develop universal vaccines against constantly mutating pathogens. OligoDOMTM is specifically designed to trigger potent T-cell responses. Osivax combines its T-cell technology with antibody-based vaccines to develop a next generation of vaccines empowering both arms of the immune system.About us



“Osivax strives to transform the high-value vaccine development landscape and improve global health through a game-changing technology designed to provide long-term protection against highly mutating viruses. We have assembled a strong and highly capable team of experts collectively dedicated to making universal vaccines available to people worldwide.”

“With the oligoDOM self-assembling nanoparticles technology, Osivax is unlocking an approach that enables the generation of T-cell responses against highly conserved internal antigens, a rare capability not found in many other nanoparticle technologies. This tactic may facilitate the development of universal vaccines to protect against current and future strains or antigenic variants of a particular virus. I am impressed by the results obtained with OVX836 in preclinical and clinical trials over the past few years and by the recent progress in other indications which show the potential of the oligoDOM platform.”

“Osivax is building upon its cutting-edge technology oligoDOM, an approach that triggers strong cellular immune responses against internal and conserved antigens of viruses to develop universal vaccines against all current and future virus strains or variants. In Flu, the phase 1 and phase 2a clinical trials with more than 1,200 subjects demonstrated a good safety profile, strong NP-specific cellular immune responses and a first signal of efficacy in the phase 2a trial. These results are very promising, de-risking the technology and paving the way for a field efficacy trial.”
Latest Press Releases
Osivax Secures Strategic Funding to Accelerate the Development of its Influenza Vaccine Candidates
Osivax Secures Strategic Funding to Accelerate the Development of its...
Read MoreOsivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836
Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial...
Read MoreOsivax and KM Biologics Enter Exclusive License Option Agreement for Broad-Spectrum “Universal” Influenza Vaccine in Japan
Osivax and KM Biologics Enter Exclusive License Option Agreement for...
Read More